再発/難治性多発性骨髄腫患者を対象としたLBL-034の第I/II相臨床研究
再発/難治性多発性骨髄腫患者におけるLBL-034の安全性、忍容性、薬物動態、および有効性を評価するための多施設共同、非盲検、第I/II相臨床研究
This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.
調査の概要
詳細な説明
This trial includes two parts: Phase I study and Phase II study.
The dose escalation and dose expansion studies for LBL-034 will be conducted in the phase I study to evaluate safety, tolerability and determine RP2D. In the dose escalation phase, the DLT observation period is from the first dose to 4 weeks after the prescribed dose is administered.Dose expansion or study at different dosing intervals in the expected effective dose group will be judged by the investigator and the sponsor based on the dose escalation data of LBL-034.
The efficacy of LBL-034 in the treatment of RRMM and RR PCL(plasma cell leukemia, PCL) will be assessed in Phase II study.
Phase II clinical study will be conducted after obtaining the RP2D.Determine the specific dosing regimen in Phase II based on the safety, PK and other data from Phase I clinical studies.Phase II clinical study includes 4 cohorts.This trial requires collection of biological samples from all subjects for relevant testing.
This clinical trial will enroll 342 patients in Phase I and Phase II studies.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:jin lu
- 電話番号:025-83378099
- メール:mengdongtao@leadsbiolabs.com
研究場所
-
-
Anhui
-
Wuhu、Anhui、中国、241001
- 募集
- The First Affiliated Hospital of Wannan Medical College
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100044
- 募集
- Peking University People's Hospital
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Fujian
-
Xiamen、Fujian、中国、361000
- 募集
- The First Affiliated Hospital of Xiamen University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Guangdong
-
Guangzhou、Guangdong、中国、516000
- 募集
- Sun Yat-sen University Cancer Center
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
Shenzhen、Guangdong、中国、518035
- 募集
- Shenzhen Second People's Hospital
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Guizhou
-
Guiyang、Guizhou、中国、563000
- 募集
- The Afliliated Hospital of Guizhou Medical Univeristy
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Hainan
-
Haikou、Hainan、中国、570000
- 募集
- The Second Affiliated Hospital of Hainan Medical University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Henan
-
Luoyang、Henan、中国、471003
- 募集
- The First Affiliated Hospital of Henan University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
Zhengzhou、Henan、中国、450008
- 募集
- Henan Cancer Hospital
-
コンタクト:
- dongtao meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
Zhengzhou、Henan、中国、450052
- 募集
- The First Affiliated Hospital of Zhengzhou University
-
コンタクト:
- dongtao meng
- 電話番号:025-83378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Hubei
-
Wuhan、Hubei、中国、430000
- 募集
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215006
- 募集
- The First Affiliated Hospital of Soochow University
-
コンタクト:
- dongtao meng
- 電話番号:025-83378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Jilin
-
Changchun、Jilin、中国、130000
- 募集
- The First Bethune Hospital of Jilin University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Liaoning
-
Shengyang、Liaoning、中国、117004
- 募集
- Shengjing Hospital of China Medical University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Shandong
-
Qingdao、Shandong、中国、266011
- 募集
- Qingdao Municipal Hospital
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200000
- 募集
- Shanghai Fourth People's Hospital
-
コンタクト:
- dongtao meng
- 電話番号:025-83378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030000
- 募集
- Shanxi Bethune Hospital
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
Xi’an、Shanxi、中国、710004
- 募集
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310000
- 募集
- The First Affiliated Hospital Zhejiang University School of Medicine
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
Ningbo、Zhejiang、中国、315000
- 募集
- The First Affiliated Hospital of Ningbo University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
Wenzhou、Zhejiang、中国、325000
- 募集
- The First Affiliated Hospital of Wenzhou Medical University
-
コンタクト:
- DongTao Meng
- 電話番号:02583378099
- メール:mengdongtao@leadsbiolabs.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll in the study, and sign the written informed consent form;
- Age ≥ 18 years at the time of signing the informed consent;
- Eastern Cooperative Oncology Group (ECOG) Performance Status Scale≤ 1;
- Documentation of initial diagnosis of multiple myeloma according to IMWG diagnostic criteria,or according to the IMWG 2021 diagnostic criteria, the proportion of circulating plasma cells in peripheral blood is ≥ 5%,have documentation to diagnose PCL;
- Have a life expectancy of at least 12 weeks;
- Fertile men and women of childbearing age are willing to take effective contraceptive measures (including abstinence, intrauterine devices, hormonal contraception, and correct use of condoms) from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.
Exclusion Criteria:
- Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug,or require elective surgery during the trial period;
- Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin-2, and interferon;
- Systemic use of corticosteroids or other immunosuppressants within 14 days prior to the initial use of the investigational drug;The following conditions are excluded: Treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term use of glucocorticoids for preventive therapy (e.g., to prevent contrast allergy);
- Patients with active hepatitis B or C;
- Subjects with an active infection that currently requires anti infective therapy;
- The patient has a Medical history of immunodeficiency, including HIV antibody positive;
- Women during pregnancy or lactation;
- The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LBL-034
LBL-034 for Injection; Q2W |
Q2W; intravenous infusion
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR)
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy).
|
ORR [including the rates of Strin-gent complete response(sCR),complete response (CR) ,Very good partial response(VGPR),and partial response (PR)], evaluated based on the 2016 IMWG criteria(Cohorts 1, 2, and 3) and 2013 IMWG criteria(Cohort 4), refers to the percentage of study subjects who achieve a complete response or partial response. It was used to evaluate the efficacy of LBL-034 in Phase II study . |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy).
|
|
Dose-limiting toxicities(DLT)
時間枠:The DLT observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
|
DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.DLT is defined as toxicity (possible adverse events related to LBL-034) during the DLT observation period . It was used to evaluate the safety of LBL-034 in Phase I study . |
The DLT observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
|
|
Maximum tolerated dose (MTD)
時間枠:The MTD observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
|
MTD is defined as the hightest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycles. It was used to evaluate the tolerability in Phase I. |
The MTD observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
|
|
Occurrence of adverse event (AE) and serious adverse event (SAE)
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Adverse event (AE) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0.The safety profile of LBL-034 will be assessed by monitoring the adverse event (AE) and serious adverse event (SAE) in Phase I study. |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cmax
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
Maximum drug concentration in plasma after administration. |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
|
Tmax
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
After administration,Time to reach maximum drug concentration in plasma. |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
|
Immunogenicity
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
The immunogenicity is evaluated by the incidence of anti-drug antibodies (ADA) and neutralizing antibodies (if applicable) in subjects.Immunogenicity refers to the performance that can elicit an immune response. |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
|
Minimal Residual Disease (MRD)
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
MRD-negative rate: Refers to the percentage of subjects who achieve MRD negativity at any time point after the initial dose and before disease progression or the initiation of a new anti-tumor therapy. |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
|
Duration of Response(DOR)
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
DOR is defined as the duration from earliest date of disease response (CR、PR 、iCR or iPR) until earliest date of disease progression or death from any cause(if occurring sooner than progression). |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
|
sBCMA
時間枠:From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
serum B-cell maturation antigen(Detect the change of sBCMA in serum) |
From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
|
協力者と研究者
捜査官
- 主任研究者:Jin Lu、Peking University People's Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。